SpringWorks Therapeutics Inc

SpringWorks Therapeutics — Corporate Update (November 2023)

23 slides from SpringWorks Therapeutics's corporate update, Nov 17, 2023

  1. Slide 1: Mirdametinib for NF1-PN: ReNeu Topline Results

    Mirdametinib for NF1 - PN November 16 , 2023 ReNeu Topline Results

  2. Slide 2: Forward-looking statements note

    2 Note: Unless otherwise indicated, the information presented herein is as of November 16, 2023. This presentation may contain “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, relating to our business, operations, and financial co

  3. Slide 3: Today's Agenda

    3 Today’s Agenda Sections Presenter Introduction Saqib Islam Chief Executive Officer ReNeu Phase 2b Data Jim Cassidy, MD, PhD Chief Medical Officer Program Highlights and Next Steps Badreddin Edris, PhD Chief Operating Officer Q&A All

  4. Slide 4: Introduction

    Introduction Saqib Islam Chief Executive Officer

  5. Slide 5: Positive Topline Results From ReNeu Demonstrate Mirdametinib's Potentially Transformative Benefit

    5 Positive Topline Results From ReNeu Demonstrate Mirdametinib’s Potentially Transformative Benefit for NF1 - PN Patients Note: NF1 - PN: Neurofibromatosis type 1 - associated plexiform neurofibroma. ▪ Topline data suggest class - leading potential for both children and adults with NF1 - PN ▪ Robust

  6. Slide 6: A Substantial Unmet Need Remains for a Best-in-Class Therapy for NF1-PN Patients

    6 A Substantial Unmet Need Remains for a Best - in - Class Therapy for NF1 - PN Patients Sources: (1) SpringWorks Market Research; (2) Korf, American Journal of Medical Genetics, 1999; (3) Koselugo prescribing information. Savanna, NF1 - PN patient Surgery is difficult due to infiltrative growth alo

  7. Slide 7: ReNeu Phase 2b Data

    ReNeu Phase 2b Data Jim Cassidy, MD, PhD Chief Medical Officer

  8. Slide 8: Phase 2b ReNeu Trial Summary

    8 Phase 2b ReNeu Trial Summary Note: REiNS : Response Evaluation in Neurofibromatosis and Schwannomatosis ; BICR: blinded independent central review; BID: twice daily; QoL: quality of life. ▪ Phase 2b open - label; n = 114 patients in 2 cohorts (pediatric and adults) across 50 U.S. sites ▪ 2 mg/m 2

  9. Slide 9: Baseline Patient Demographics and Disease Characteristics

    9 Baseline Patient Demographics and Disease Characteristics Note: PN: plexiform neurofibroma. Characteristic n (%) Patients enrolled 56 Median age at enrollment [range] - years 10.0 [2 – 17] Sex Male Female 26 (46) 30 (54) Location of target neurofibroma Head and Neck Lower / Upper Extremities Paras

  10. Slide 10: Best Tumor Response: Pediatric Cohort

    10Best Tumor ResponsePediatric CohortNote: BICR: blinded independent central review;cORR : confirmed objective response(1)Shows best change in tumor volume achieved at any point, including unconfirmed partial responses.(2)Participants that discontinued study prior to any ontreatment MRI assessment.#

  11. Slide 11: Treatment Duration and Response: Pediatric Cohort

    11 Treatment Duration and Response Pediatric Cohort ▪ Median duration of treatment was 22.0 months ▪ Median time to first response was 7.9 months ‒ 45% of patients had their onset of confirmed response by Cycle 5 assessment ( 4.2 months) ▪ Median duration of response was not reached ▪ 28 patients re

  12. Slide 12: Patient-Reported Outcomes: Pediatric Cohort

    12 Patient - Reported Outcomes Pediatric Cohort Scale p - Value for Change from Baseline (1) Target Tumor Pain - Numeric Rating Scale (NRS - 11) (2) (n=15) 0.003 Pain Interference Index (PII) (3) Self - Report (n=20) Parent Proxy (n=18) 0.004 0.016 Pediatric Quality of Life Inventory (PedsQL) (4) –

  13. Slide 13: Safety Summary: Pediatric Cohort

    13 Safety Summary Pediatric Cohort (1) Composite adverse event including dermatitis acneiform, rash, rash maculo - papular, rash erythematous, acne, seborrheic dermatiti s, exfoliative rash, papule, rash papular , dermatitis, rash macular, rash pruritic. (2) Dose interruptions due to treatment - rel

  14. Slide 14: Best Tumor Response: Adult Cohort

    14Best Tumor ResponseAdult CohortNote: BICR: blinded independent central review;cORR : confirmed objective response(1)Shows best change in tumor volume achieved at any point, including unconfirmed partial responses.(2)Participants that discontinued study prior to any ontreatment MRI assessment.#Pati

  15. Slide 15: Treatment Duration and Response: Adult Cohort

    15 Treatment Duration and Response Adult Cohort Evaluable Patients End of treatment phase (24 cycles (1) ) × Progressive disease Death (2) Objective response confirmed (1) 4 - week cycles of 3 weeks on, 1 week off. Treatment phase ends 3 weeks into final cycle. (2) One patient death due to COVID - 1

  16. Slide 16: Patient-Reported Outcomes: Adult Cohort

    16 Patient - Reported Outcomes Adult Cohort Scale p - Value for Change from Baseline (1) Target Tumor Pain Numeric Rating Scale (NRS - 11) (2) (n=21) <0.001 Pain Interference Index (PII) (3) (n=22) <0.001 Pediatric Quality of Life Inventory (PedsQL) (4) – Total Score (n=34) 0.009 Pediatric Quality o

  17. Slide 17: Safety Summary: Adult Cohort

    17 Safety Summary Adult Cohort (n=58) TEAEs ≥ 20% Subjects TRAEs Preferred Term All Grades – n (%) ≥ Grade 3 – n (%) All Grades – n (%) ≥ Grade 3 – n (%) Any TEAE 58 (100) 21 (36) 57 (98) 9 (16) Rash (1) 54 (93) 6 (10) 54 (93) 6 (10) Dermatitis acneiform 45 (78) 5 (9) 45 (78) 5 (9) Diarrhea 34 (59)

  18. Slide 18: Program Highlights and Next Steps

    Program Highlights and Next Steps Badreddin Edris, PhD Chief Operating Officer

  19. Slide 19: Mirdametinib Positioned to Address Substantial Unmet Needs in NF1-PN

    19 Sources: (1) Lammert et al., Arch Dermat , 2005. U.S. Census Data; (2) Fisher et al., Neuro - Oncology, 2022. (3) SpringWorks market research. ~100,000 Individuals with an NF1 diagnosis in the U.S. (1) ~40,000 Patients living with NF1 - PN in the U.S. (2,3) Mirdametinib Is Positioned to Address t

  20. Slide 20: Regulatory Status and Next Steps

    20 Regulatory Status and Next Steps Regulatory Designations: ▪ Orphan Drug Designation for NF1 granted by FDA and European Commission and Fast Track Designation for NF1 - PN granted by FDA ▪ Rare Pediatric Disease Designation granted by FDA in July 2023 Upcoming Submissions: ▪ Plan to request Pre -

  21. Slide 21: Positive Results From ReNeu Advance Our Goal of Two Potential Approvals by 2025

    21Positive Results From ReNeuAdvance Our Goal of Two Potential Approvals by 2025(1)Gounder et al., NEJM, 2023.Note: PDUFA: Prescription Drug User Fee Act; NF1-PN: Neurofibromatosis type 1-associated plexiform neurofibroma.21Mirdametinib?If approved, would be the first FDA-approved therapy for desmoi

  22. Slide 22: Thank You

    Thank You THERAPEUTICS

  23. Slide 23: Q&A

    23 Jim Cassidy, MD, PhD Chief Medical Officer Q&A Saqib Islam Chief Executive Officer Badreddin Edris, PhD Chief Operating Officer

SpringWorks Therapeutics — Corporate Update (November 2023) on 6ix